A phase I clinical trial of radiolabeled immunotherapy with humanized LL2 [epratuzumab Y-90] in patients with refractory or recurrent non-Hodgkin's lymphoma

Trial Profile

A phase I clinical trial of radiolabeled immunotherapy with humanized LL2 [epratuzumab Y-90] in patients with refractory or recurrent non-Hodgkin's lymphoma

Discontinued
Phase of Trial: Phase I

Latest Information Update: 08 Jan 2008

At a glance

  • Drugs Epratuzumab Y-90 (Primary)
  • Indications B cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 08 Jan 2008 Status changed from in progress to discontinued.
    • 01 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top